Faron Pharmaceuticals Oy (AIM:FARN, OTC:FPHAF) highlighted the progress made in the first half in developing its cancer immunotherapy candidate Bexmarilimab.
The clinical stage biopharmaceutical company peviously revealed that a phase I/II MATINS study showed 100% of checkpoint refractory skin cancer and bile duct cancer patients treated with Bexmarilimab survived for a year.
NetScientific, an international life sciences and sustainability technology investment group, has completed a US$35mln debt financing agreement for its portfolio company PDS Biotechnology Corporation (NASDAQ:PDSB).
Led by the Horizon Technology Finance Corporation, the term loan will be used to support the ongoing clinical development of PDS0101 and other product candidates within the company's pipeline and for general working capital purposes.
Greatland Gold PLC (AIM:GGP, OTC:GRLGF) said it raised about £30mln (US$35mln) via an oversubscribed placing to fund the development of ongoing licenses.
The placing, at a price of 8.2p per ordinary share, will accelerate drilling at the Havieron deposit and grow the wider resource alongside joint venture partner Newcrest Mining Ltd.
Zephyr Energy PLC said it acquired an additional 1,920 acres in the Paradox Basin, Utah, that it expects has immediate development potential.
Zephyr's technical team estimates the acquisition will add more than 4 million barrels of oil equivalent of additional 2C net resources to its flagship asset.
Powerhouse Energy PLC interim chairman Keith Riley said he is encouraged by the growing interest outside of the UK for its waste-to-energy projects.
Since its half-year end in June, Powerhouse has signed projects in Ireland and Poland with its development partner Hydrogen Utopia.